breakthrough therapy – Clinical Research Made Simple

Accelerated Approval vs Traditional Pathways Explained

August 25, 2025

Accelerated Approval vs Traditional Pathways Explained Comparing Accelerated and Traditional Drug Approval Pathways Introduction: The Landscape of FDA Approval Mechanisms The U.S. Food and Drug Administration (FDA) has created multiple regulatory pathways to balance the need for rapid access to life-saving treatments with the requirement for robust evidence of safety and efficacy. Among these, the…

NDA/BLA/MAA Filings, Regulatory Submissions and Approvals

Combining Orphan Drug and Breakthrough Designations: Opportunities and Challenges

August 19, 2025

digi

Combining Orphan Drug and Breakthrough Designations: Opportunities and Challenges Maximizing Rare Disease Drug Development with Orphan and Breakthrough Designations Introduction: Strategic Use of Dual Designations Rare disease therapies face considerable scientific and logistical challenges due to limited patient populations, fragmented natural history data, and evolving regulatory expectations. Fortunately, the FDA and other global regulators offer…

Rare and Orphan Disease Trials, Regulatory Frameworks